Xenon Pharmaceuticals Inc. (XENE)
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were absolutely eye-popping, but follow major news that has led investors to re-rate each stock.
Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript
Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript
Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked
Xenon Pharmaceuticals Inc. surged on positive Phase 3 data for azetukalner in focal onset seizures, showing best-in-class placebo-adjusted efficacy. XENE plans an NDA submission for azetukalner in Q3 2026, targeting both epilepsy and neuropsychiatric indications, with additional pivotal trials ongoing. Despite robust efficacy and a differentiated profile, XENE faces a crowded anti-seizure market, notable adverse event rates, and potential commercial execution risks.
Xenon Pharma's epilepsy drug meets main goal in late-stage trial
Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of a late-stage trial, showing a statistically significant reduction in focal onset seizures.
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout
Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder treatment. XENE's $555M cash position supports operations into 2027, reducing near-term financing risk despite increased R&D and G&A expenses. Azetukalner's Phase 3 epilepsy and depression trials, strong long-term efficacy, and unique mechanism offer significant commercial upside.
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
Polarean enters Asia with first Xenon MRI deal in Taiwan
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has secured its first foothold in Asia after National Taiwan University Hospital agreed to install one of the company's Xenon MRI research systems. The deal has been arranged through Philips, Polarean's long-standing strategic partner, and supported by Sumtage, the company's newly appointed distributor in Taiwan.
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. ( XENE ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Colleen Alabiso Ian Mortimer - President, CEO, Principal Accounting Officer & Director Christopher Kenney - Chief Medical Officer Thomas Kelly - Chief Financial Officer Darren Cline - Chief Commercial Officer and Member of Executive Team Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Johoon Kim - RBC Capital Markets, Research Division Charles Moore - Robert W. Baird & Co. Incorporated, Research Division Dina Ramadane - BofA Securities, Research Division Joseph Thome - TD Cowen, Research Division Brian Balchin - Jefferies LLC, Research Division Presentation Operator Good day, everyone, and thank you for standing by.
